久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Local private firms to step up innovation

By LIU ZHIHUA | China Daily | Updated: 2021-08-10 09:49
Share
Share - WeChat
A researcher works at Clover Biopharmaceuticals' R&D center in Chengdu, Sichuan province. [Provided to China Daily]

Clover received local government support to build a commercial manufacturing facility that completed construction in early 2020 in Huzhou, Zhejiang province.

"Even though the company's drugs and vaccines were only in the preclinical stage then, their support allowed us to build a large facility that ended up being very important for our COVID vaccine program," Liang said.

He also mentioned that the NMPA and its Center for Drug Evaluation have continued to expand their own capabilities, and the regulatory review timelines have been greatly shortened.

The NMPA and CDE have also had a higher willingness to work together with biotech companies, and to have scientific and strategic discussions, he added.

Shi Lichen, founder of Beijing Dingchen Consultancy, said Chinese pharmaceutical and biotech companies, among which many are non-State-owned, used to develop few self-developed original or innovative drugs. But things are changing mainly due to the improved regulatory environment, the stronger play of market mechanisms and booming venture capital/private equity investment.

"China's medicine reforms in recent years are driving Chinese companies to focus more on new drug R&D and innovation to optimize product portfolios toward medium-to-high end returns, instead of simply profiting from the production and sales of low-quality generics," Shi said.

Wei said most of the Chinese pharmaceutical enterprises focused on generics before regulatory reforms in 2015, but there are now a growing number of biotech companies developing innovative drugs.

On the policy side, China joined the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, in 2017, and is actively implementing guidelines to encourage genuine indigenous innovations.

In terms of industry practice, many Chinese pharmaceutical companies are establishing R&D centers and running clinical trials abroad. Cross-border deals have been active in the past few years, especially with a growing number of noticeable out-licensing deals, pointing to the future of "innovated in China", not just "made in China", he added.

Industry insiders also said the booming VC/PE investment in China's pharmaceuticals sector has been further propelled by the pandemic and capital market reforms-such as the Science and Technology Innovation Board accepting listings from unprofitable companies and thus providing an exit mechanism for investors.

According to global consultancy McKinsey & Co, there has been a strong rebound of healthcare VC/PE investment in 2020 after a decline in 2019. The total amount of VC/PE investment in the sector during the first half in 2020 had already exceeded that for the whole of 2019.

Li Gang, partner of private investment bank CEC Capital, said accelerating reforms in China's capital market, including a registration-based system for IPOs and lower financial listing requirements, have provided investors clear exit strategies and thus have injected new momentum into healthcare investment.

Liang said when he joined Clover in 2016, Chinese investors were still mainly looking at generics and biosimilars, while now there are many VC funds in China that want to support early-stage biotech companies, and some venture capital funds prefer to do Angel investing rounds, or even form companies from scratch.

"The changing environment in the capital markets, with more funding for innovation, continues to support and foster continued growth of innovation in private Chinese pharmaceutical and biotech companies," Liang said.

However, despite fast growth and increasing presence in the global industry arena, there is still a long way to go for China's non-State-owned pharmaceutical and biotech industry to become globally influential, experts said.

Only 13 pharmaceutical and healthcare enterprises made the list of the top 500 Chinese private enterprises last year, which was released by the All-China Federation of Industry and Commerce.

|<< Previous 1 2   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 欧美一级毛片大片免费播放 | 欧美精品高清在线观看 | 日韩精品一区二区三区中文字幕 | 日韩在线视频免费不卡一区 | 国产欧美日韩综合精品一区二区 | 日韩性大片免费 | 国产精品久久久久久久久久影院 | avtt亚洲一区中文字幕 | 波多野结衣视频免费在线观看 | 日韩a毛片免费全部播放完整 | 一区二区三区四区视频在线 | 精品 日韩 国产 欧美在线观看 | 欧美成人免费全网站大片 | 久草中文在线 | 成熟的女性强烈交性视频 | 久久精品综合 | 我们2018在线完整免费观看 | 日韩在线观看不卡 | 性感美女一级片 | 日产日韩亚洲欧美综合搜索 | 国产精品九九 | 日韩精品在线观看免费 | 国产一级生活片 | 手机看片手机在线看片 | a级毛片毛片免费观看永久 a级毛片毛片免费很很综合 | 日本一线a视频免费观看 | 久草久草久草 | 天天澡夜夜澡狠狠澡 | 国产欧美专区在线观看 | 久久久久久免费一区二区三区 | 久久免费精品 | 日韩精品在线播放 | 国产男女乱淫真视频全程播放 | 精品免费久久久久欧美亚一区 | 中文字幕在线无限2021 | 成人精品亚洲 | 国产99精品在线观看 | 精品无人区一区二区三区a 精品午夜国产在线观看不卡 | 国产高清无专砖区2021 | 国产91网址| 午夜三级a三点 |